ACTION receives $2 million grant from Parent Project Muscular Dystrophy (PPMD) to expand muscular dystrophy focused research and quality improvement initiatives
ACTION centers collaborate with Abbott to update FDA labeling of the HeartMate 3™ LVAD for use in pediatrics CINCINNATI — The FDA has updated Abbott’s HeartMate 3™ LVAD labeling to treat children
Check out this upcoming ACTION oral presentation! Support Michael Catalano, et al. at the 2026 Society of Thoracic Surgeons (STS) Annual Meeting in January!
Early data from 500 males in the ACTION dystrophinopathy registry show substantial cardiac involvement and broad use of cardioprotective therapies. Ongoing follow-up will define the modern natural history of cardiomyopathy in dystrophinopathy.
At just 10 weeks old, Marylu survived cardiac arrest, multiple surgeries, and a rare diagnosis—emerging with a new heart and extraordinary strength. Her journey is a powerful testament to faith, courage, and miracles.
Faith, Fight, and a Second Heart: Marylu’s Story Read More »
What began as a Navy medic’s desire to heal became a lifelong mission to bring life-sustaining technology to patients in heart failure. As a driving force behind the HeartMate LVAD series, CentriMag, and PediMag systems, his leadership helped shape modern circulatory support and bring hope to countless patients worldwide.
Translating Vision into Reality: An Interview with Kurt Dasse, PhD Read More »
Driven by the loss of his grandfather, Dr. Rich Wampler revolutionized how the world treats heart failure. From the creation of the first implantable rotary blood pump to the development of the HeartMate II and HeartWare HVAD, his groundbreaking work has saved hundreds of thousands of lives – and continues to shape the future of circulatory support.
The Heart of Innovation: Dr. Rich Wampler’s Journey from Loss to Life-Saving Discovery Read More »
Happy Fall to All! We have many exciting updates to share, such as new pediatric Impella education materials for Providers and Patients/Families, a debrief of our incredibly successful first VAD Bootcamp, and many new publications and other tools. As we move into the holiday season, we reflect on our continued appreciation and thankfulness for the engagement and collaboration from all stakeholders that continue to excel our research, quality improvement, education, and advocacy efforts.
The Pulse — Nov 2025 Read More »
ACTION is excited to announce the release of the Impella® Heart Pump Patient Education Handbook. This educational tool will help patients learn, stay organized, and feel empowered.
NEW! Impella Patient Education Handbook Read More »
A new multi-center study explores the off-label use of SGLT2 inhibitors in children and adolescents with heart failure, highlighting real-world safety data and underscoring the need for prospective trials.
Use of SGLT2 inhibitors in pediatric heart failure: a multi-center study Read More »
Prevalence and Risk Factors for Ventricular Assist Device-Associated Infection in Children: An Analysis of the ACTION Registry Support Madeline Townsend, et al. at the 2025 AHA Scientific Session in November!
